First quality-of-life data of a sequential dose-dense regimen in advanced ovarian cancer: A multicenter phase II study of the Northeastern German Society of Gynecological Oncology.

G. Oskay-Özcelik,R. Richter,K. Pietzner,H. Hindenburg,H. Sommer,R. Chekerov,O. Camara,E. Keil,J. Einenkel,W. Lichtenegger,J. Sehouli
DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.5071
IF: 45.3
2011-05-20
Journal of Clinical Oncology
Abstract:5071 Background: The objective of this study was to examine the impact of a sequential dose dense schedule of carboplatin and paclitaxel on quality of life (QoL). METHODS In this multicenter phase II trial patients with advanced ovarian cancer received four cycles of carboplatin followed by 12 cycles of weekly paclitaxel after primary radical surgery (abstr. 5533; J Clin Oncol 2007). QoL (QLQ-C30; QLQ-Ov28) was analyzed regarding the effect of carboplatin and paclitaxel separately at end of treatment (EOT) and 6, 12, and 24 months later. RESULTS Overall 87 out of 104 eligible patients (84%) participated for at least one QoL-assessment during the treatment, but only 24 patients did likewise 2 years after EOT. At baseline all QLQ-C30 scales and symptoms were significantly worse on average than age adjusted expected values of the general population. From then QoL improved in general. During chemotherapy with paclitaxel most functioning scales and symptoms worsened slightly but not significantly. But peripheral neuropathy and chemo side-effects increased with clinically important differences. After EOT most QoL scores were similar wih those of general population, but physical functioning and fatigue were worse, sexual functioning remained very low. Worries about future health and peripheral neuropathy were rated problematic for some patients. CONCLUSIONS QoL was generally favorable and was mainly affected by the paclitaxel weekly schedule. During chemotherapy and after EOT QoL was improved. Therefore the QoL data support a dose dense regimen.
What problem does this paper attempt to address?